ICCM
IceCure Medical Ltd
NASDAQ · Healthcare · Medical - Devices · IL
$2.23
+1.36%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$7.64M
MomentumView details →
1D Return
+1.36%
YTD Return
−87.81%
RSI (14)
32.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$7.64M
RSI (14)
32.4
MomentumView details →
1D Return
+1.36%
YTD Return
−87.81%
SummaryUpdated Jun 1, 2026
IceCure Medical Ltd (NASDAQ:ICCM) is an Israeli medical device company founded in 2006 and headquartered in Caesarea, Israel. The company went public on NASDAQ in August 2021. IceCure specializes in developing and commercializing cryoablation technology, which uses extreme cold to destroy diseased tissue, particularly for cancer treatment. The company's flagship product, the ProSense system, is designed to treat breast tumors through minimally invasive cryoablation procedures. IceCure is currently awaiting FDA approval for its ProSense system in the United States while maintaining commercial operations in international markets.
Similar companies
Latest newsMore news →
IceCure Medical entered into an exclusive distribution agreement with Scovas Medical for the distribution of its ProSense cryoablation systems in the Netherlands for breast cancer and interventional oncology.11d agoIceCure Medical announced that the Institutional Review Board of West Cancer Center & Research Institute approved its post-marketing ChoICE Study for ProSense cryoablation in low-risk breast cancer treatment.15d agoIceCure Medical Ltd held its Q2 2026 earnings call on August 12, 2026.23d ago